PHERECYDES Strengthens its Corporate Links with ERYTECH to Prepare the Strategic Combination
Summary
Finexsi, acting as an independent appraiser (commissaire à la fusion), has reviewed the fairness of the exchange ratio for the Proposed Merger. The proposed strategic combination leverages the expertise and complementary resources of both companies to accelerate the clinical development of a global extended phage therapy player, designed to combat antibiotic resistance, recognized as a major public health issue. Thanks to the strong commitment and operational coordination of the two teams, considerable work has been performed between both companies to initiate the implementation of the numerous synergies. The Strategic combination will enable to accelerate PHERECYDES‘s ambitious clinical plan, especially in the United States, creating high value for shareholders and patients. Headquartered in Nantes, Pherecydes Pharma has a team of around thirty experts from the pharmaceutical industry, biotechnology sector and academic research.